Status:
UNKNOWN
Benefits of Therapy With Virtual Reality Exposure in the Treatment of Cocaine Use Disorders
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Fondation de l'Avenir, France
Conditions:
Addiction
Cocaine-Related Disorders
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Cocaine addiction is a multifactorial disease with important consequences: somatic, psychiatric... The number of applications for treatment for cocaine addiction is gradually increasing from year to y...
Detailed Description
In France, according to the Health Barometer 2017, cocaine testing has seen two decades of increases from 1.2% in 1995 to 5.6% in 2017, making it the second most widely used illicit substance. About 5...
Eligibility Criteria
Inclusion
- suffering from a cocaine use disorder with craving criteria present according to the criteria of DSM 5
- wanting to stop cocaine use
- able to give informed consent to participate in research
- Covered by a Social Security plan.
Exclusion
- Patient with:
- psychiatric comorbidities (DSM 5) unstabilized
- dipsomaniac alcoholism
- an anteriority of one or more hypomanic or manic episodes
- unstabilized psychosis
- an unstabilized depression
- a severe suicidal risk
- a syndrome of dependence on products other than cocaine or tobacco
- unstabilized anxiety
- problems that hinder participation in 3D exposure, as a tendency to dissociation; phobias of the type of information (panic attacks and hypochondria...) severe dizziness...
- cognitive problems limiting or preventing the possibility of implementing coping or managing emotions or stimuli and disabilities to complete questionnaires
- a language barrier
- a serious intercurrent pathology
- the need for weekly individual follow-up Patient in a protected population such as pregnant women, lactating women, patients under guardianship, guardianship, deprived of freedoms, or in safeguarding justice
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04280900
Start Date
June 1 2020
End Date
December 31 2021
Last Update
February 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont Ferrand
Clermont-Ferrand, Auvergne, France, 63000